KYMR says it accelerated STAT6 trial enrollment and outlined expansion plans
KYMR highlighted accelerated enrollment in pivotal STAT6 trials for atopic dermatitis and asthma, citing a strong safety profile. It also plans aggressive expansion across indications, with a focus on pediatric populations, and continued IRF5 program advancement.